Suplasyn/Suplasyn 1-Shot

Sodium hyaluronate.

Each syringe contains: (See table.)
Click on icon to see table/diagram/image

HYALURONIC ACID (HA) is a normal component of the synovia and plays a central role in maintaining the physiological internal environment of the joint.
Composition: Viscoelastic solution of a defined molecular weight of purified hyaluronic acid, produced by fermentation.

Hyaluronic acid is the prototype of a wide range of saccharide biopolymers (glycosaminoglycans), important components of all extracellular tissue structures, including cartilage and synovial fluid. The active substance of SUPLASYN is a hyaluronic acid of defined molecular chain length with a high degree of purity. The introduction of SUPLASYN into the synovial space will assist in the normalization of the joint following arthrocentesis.

SUPLASYN and SUPLASYN 1-SHOT are indicated for the symptomatic treatment of osteoarthritis. SUPLASYN has been shown to be beneficial in osteoarthritis for the management of pain and improvement in physical function of joints. More than one joint may be treated at the same time.

Depending upon joint size, up to 6 ml may be administered intra-articularly.
SUPLASYN: The recommended schedule for SUPLASYN supplied in a 2ml syringe is 1 injection per week for 3 weeks, but up to 6 may be given depending on patient's condition.
SUPLASYN 1-SHOT: Intended for single administration.
Use strict aseptic technique. Discard any unused portion of the syringe. To use the pre filled syringe, remove the Luer lock cap, attach a suitable cannula (recommended is 21 - 25 G depending on joint) and secure it by turning slightly. GRADUATION ON THE SYRINGE LABEL IS TO BE USED AS A GUIDE ONLY.

Do not administer to patients with known hypersensitivity reactions. Respect usual precautions and contraindications for any intra-articular injection. Do not inject intra-vascularly. SUPLASYN should not be used in patients presenting an inflammation/irritation of the joint, since adverse events more commonly occur in patients with already existing joint inflammation/irritation. As no clinical evidence is available on the use of Hyaluronic Acid in children, pregnant and lactating women, treatment with SUPLASYN is not recommended in these patients. The patient should rest 24-48 hours after the injection and avoid any strenuous activity over the full course of the treatment.
Transient short duration pain may occur following intra-articular introduction. The affected joint may show a mild local reaction like pain, feeling of heat, hyperthermia, redness, effusion, irritation, and swelling/inflammation. If these symptoms occur, rest the affected joint and apply ice locally. Symptoms subside within days for most of the patients. In some cases, mild local reactions such as pain, irritation, swelling/joint inflammation and effusion may be significantly enhanced and much more severe as an expression of hypersensitivity. In such cases, a therapeutic intervention could be necessary, e.g. aspiration of joint fluid. Local adverse reactions could be accompanied by systemic reactions such as fever, chills, or cardiovascular reactions, and in rare cases anaphylactic reactions. In extremely rare circumstances, rash/itching, urticaria, synovitis, and a drop in blood pressure have been reported following the administration of SUPLASYN. Discontinue use if adverse reactions are experienced. Avoid using SUPLASYN with sterilising or sanitising agents containing quaternary ammonium salts solutions.

Do not use if blister is damaged. To be used by a physician only. For single use only. Discard unused portion of syringe. Reuse may create a risk of contamination and/or cause patient infection or cross infection.

Do not administer to patients with known hypersensitivity reactions. Respect usual precautions and contraindications for any intra-articular injection. Do not inject intra-vascularly. SUPLASYN should not be used in patients presenting an inflammation/irritation of the joint, since adverse events more commonly occur in patients with already existing joint inflammation/irritation. As no clinical evidence is available on the use of Hyaluronic Acid in children, pregnant and lactating women, treatment with SUPLASYN is not recommended in these patients. The patient should rest 24-48 hours after the injection and avoid any strenuous activity over the full course of the treatment.
Transient short duration pain may occur following intra-articular introduction. The affected joint may show a mild local reaction like pain, feeling of heat, hyperthermia, redness, effusion, irritation, and swelling/inflammation. If these symptoms occur, rest the affected joint and apply ice locally. Symptoms subside within days for most of the patients. In some cases, mild local reactions such as pain, irritation, swelling/joint inflammation and effusion may be significantly enhanced and much more severe as an expression of hypersensitivity. In such cases, a therapeutic intervention could be necessary, e.g. aspiration of joint fluid. Local adverse reactions could be accompanied by systemic reactions such as fever, chills, or cardiovascular reactions, and in rare cases anaphylactic reactions. In extremely rare circumstances, rash/itching, urticaria, synovitis, and a drop in blood pressure have been reported following the administration of SUPLASYN. Discontinue use if adverse reactions are experienced. Avoid using SUPLASYN with sterilising or sanitising agents containing quaternary ammonium salts solutions.

As no clinical evidence is available on the use of Hyaluronic Acid in pregnant and lactating women, treatment with SUPLASYN is not recommended in these patients.

Store between 4°C and 25°C. Do not freeze.
Bring to room temperature before injection.

Other Drugs Acting on Musculo-Skeletal System

M09AX01 - hyaluronic acid ; Belongs to the class of other drugs for disorders of the musculo-skeletal system.

NP